Use of adipose tissue-derived stromal stem cells in treating fistula

1. A method of combination therapy for treatment of graft-versus-host disease in a subject comprising administering intravenously to the subject a population of cells comprising isolated multipotent stromal stem cells isolated from bone-marrow or adipose tissue, wherein (a) at least 80% of the isolated multipotent cells express CD29, CD44, CD90, and CD105; (b) less than 5% of the isolated multipotent cells express CD14, CD34, and CD45, and (c) the population of cells are allogeneic to the subject and were not matched for MHC compatibility, wherein the population further comprises a pharmaceutically acceptable carrier, wherein said carrier comprises HSA, wherein the population of multipotent stromal stem cells were passaged at least 4 times prior to administration, wherein the population of multipotent stromal stem cells were cryopreserved at a concentration of at least about 5×10 6 cells/mL prior to administration, wherein the population of multipotent stromal stem cells were thawed prior to administration, wherein the subject was previously administered a therapeutic agent, wherein the therapeutic agent is an anti-inflammatory agent, a corticosteroid, or an immunosuppressive agent.

2. The method of claim 1 , wherein the combination therapy includes repair or regeneration of tissues.

3. The method of claim 1 , wherein the population of cells were isolated from bone marrow.

4. The method of claim 1 , wherein the isolated multipotent stromal stem cells were isolated by a method that comprises:

(a) collecting adipose tissue or bone-marrow;

(b) obtaining a cell suspension by enzymatic digestion;

(c) sedimenting and resuspending the cells in a culture medium; and

(d) culturing the cells on a solid surface, and eliminating cells that show no adhesion to said solid surface.